1692280449     

A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients / Giorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te-Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, Kambiz Mansouri, Volker Wacheck, Gee-Chen Chang

Scagliotti, Giorgio V. [Verfasserin/Verfasser]

Moro-Sibilot, Denis [Verfasserin/Verfasser] ; Kollmeier, Jens [Verfasserin/Verfasser] ; Favaretto, Adolfo [Verfasserin/Verfasser] ; Cho, Eun Kyung [Verfasserin/Verfasser] ; Grosch, Heidrun [Verfasserin/Verfasser] ; Kimmich, Martin [Verfasserin/Verfasser] ; Girard, Nicolas [Verfasserin/Verfasser] ; Tsai, Chun-Ming [Verfasserin/Verfasser] ; Hsia, Te-Chun [Verfasserin/Verfasser] ; Brighenti, Matteo [Verfasserin/Verfasser] ; Schumann, Christian [Verfasserin/Verfasser] ; Wang, Xuejing Aimee [Verfasserin/Verfasser] ; Wijayawardana, Sameera R. [Verfasserin/Verfasser] ; Gruver, Aaron M. [Verfasserin/Verfasser] ; Wallin, Johan [Verfasserin/Verfasser] ; Mansouri, Kambiz [Verfasserin/Verfasser] ; Wacheck, Volker [Verfasserin/Verfasser] ; Chang, Gee-Chen [Verfasserin/Verfasser]

Journal of thoracic oncology : JTO ; official publication of the International Association for the Study of Lung Cancer . - Amsterdam : Elsevier ; Philadelphia, Pa. : Lippincott Williams & Wilkins, 2006-. - Bd. 15 (2020), 1, S. 80-90 = 11 S.

Englisch

Available online - 14 October 2019. - Gesehen am 11.03.2020

Elektronische Ressource: Zugang über Resolving-System (Lizenzangabe: Lizenzpflichtig)

Elektronische Ressource: Zugang beim Produzenten (Lizenzangabe: Lizenzpflichtig)

Digital Object Identifier (DOI): 10.1016/j.jtho.2019.10.003

Acquired resistance ; Antibody ; First-line mutation ; MET ; NSCLC

The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET) is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in resistance to EGFR inhibitors. Emibetuzumab, a humanized immunoglobulin G4 monoclonal bivalent MET antibody, blocks ligand-dependent and ligand-independent hepatocyte growth factor/MET signaling. This phase 2 study compared erlotinib with and without emibetuzumab in first-line treatment of EGFR-mutant metastatic NSCLC.